Scale-up and deliver allogeneic cell therapies to large patient populations

Sponsor

Cell therapy has become a therapeutic reality for many patients, with several successful autologous drug approvals over the last few years.

Beyond the known off-the-shelf benefits provided, allogeneic cell therapy cost structure makes this technology substantially more economical, increasing the ability of cell therapy to treat large patient populations, with many developers currently heavily investing in this field.

As allogeneic cell therapy continues its exponential growth, a scale-appropriate model to start clinical trials early, while aiding a smooth transition into large scale when the need comes, will be required for companies to successfully deliver from first-in-human to commercialization.

In this webinar, we will cover how the use of outstanding technology, alongside a tried-and-tested standardized systematic approach and reliable analytics, can enable you to deliver a robust and commercially viable process; ensuring an adequate supply to achieve your therapeutic and commercial goals.

The challenges associated with allogeneic cell therapy manufacturing
How the latest technology linked with a tried-and-tested standardized approach can successfully move you through the product lifecycle
How to transition from a scale-appropriate model into a commercially viable large-scale process, designed to cure the masses
How a stirred tank bioreactor platform can support large-scale cell manufacturing

Marcos Langtry

Director, Commercial Development, Allogeneic Cell and Gene Therapy, Lonza

Marcos Langtry is Director Commercial Development, Allogeneic Cell Therapy at Lonza. He is responsible for the allogeneic commercial strategy, current and future offerings, and portfolio optimization. Before joining Lonza, Marcos Langtry held several senior level positions with TiGenix, Astra Zeneca and Sanofi in the areas of external manufacturing, process development, technical operations and industrial strategy; where he has acquired extensive experience with aseptically filled, biologic and cell therapy products.

Krishna Panchalingam, PhD

Associate Director, Development Services, Cell and Gene Therapy, Lonza

Dr. Panchalingam is an Associate Director of Process Development, Cell and Gene Technologies at Lonza, focusing on the development of cell and gene therapies for clinical and commercial applications. He has over 16 years of experience in stem cell bioengineering, bioprocessing and in the cell and gene therapy (C>) field. Dr. Panchalingam holds a PhD degree in Chemical Engineering from the University of Calgary (Calgary, Canada) where he focused on the development of viable, scalable, and defined bioprocesses in the field of regenerative medicine.

Inbar Friedrich Ben Nun

Director, R&D, Cell and Gene Therapy, Lonza

Dr. Inbar Friedrich Ben-Nun is Director Research and Development, Cell Therapy at Lonza. She has joined Lonza 10 years ago as a Scientist, after completing Post-doctoral research at the Scripps Research Institute, La Jolla, where she obtained an extensive experience with iPSCs. In her current role as a R&D Director at Lonza, Inbar is responsible for driving and executing innovating solutions for allogeneic cell therapy processes and platforms.

Watch now